Online citations, reference lists, and bibliographies.
← Back to Search

Weakening Impact Of Excessive Human Serum Albumin (eHSA) On Cisplatin And Etoposide Anticancer Effect In C57BL/6 Mice With Tumor And In Human NSCLC A549 Cells

Z. Yang, Ting Zhou, Yuanchi Cheng, Mingming Li, Xianglin Tan, F. Xu
Published 2016 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Excessive human serum albumin (eHSA) impact on anticancer effects is inconsistent. We explored the outcome of cisplatin (DDP)/etoposide (VP-16) plus eHSA in vivo and in vitro. C57BL/6 mice with tumor were used to compare the efficacy of DDP/VP-16 alone and DDP/VP-16+eHSA. Blood albumin was measured to confirm whether eHSA elevate its level. Western blotting assay were used to measure the expression of ERCC1/TOP2A in tumor tissues. Cell proliferation, mRNA, and protein expression of ERCC1/TOP2A were also assayed to compare two groups in A549 cells. Furthermore we evaluated eHSA impact on cell proliferation in RNAi targeting ERCC1/TOP2A in A549 cells, respectively. eHSA reduced the anticancer effect of DDP/VP-16 without altering albumin level, increased protein expression of ERCC1/TOP2A, respectively in mice. Similarly, eHSA increased mRNA and proteins expression of ERCC1/TOP2A in A549 cells. In RNAi A549 cells, however, eHSA no longer weakened but enhanced the anticancer effect of DDP, while no longer altered the effect of VP-16. Our findings suggested that eHSA weaken the anticancer effect of DDP/VP-16 via up-regulating ERCC1/TOP2A expression, respectively. Further molecular mechanism studies are warranted to investigate whether eHSA is not conducive to lung cancer chemotherapy.
This paper references
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
K. Olaussen (2006)
Comparative analysis the binding affinity of mycophenolic sodium and meprednisone with human serum albumin: Insight by NMR relaxation data and docking simulation.
X. Ma (2016)
DNA repair by ERCC 1 in non - small - cell lung cancer and cisplatinbased adjuvant chemotherapy
K. A. Olaussen (2006)
A Comprehensive Computational Study of the Interaction between Human Serum Albumin and Fullerenes.
G. Leonis (2015)
Increased expression
J. He (2015)
Type III hypersensitivity reaction with immune complex deposition in 2 critically ill dogs administered human serum albumin.
Cassandra Powell (2013)
Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin.
P. Alam (2016)
Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
P. Verdier-Pinard (2003)
The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells
P. Chen (2016)
A comparison of albumin and saline for fluid resuscitation in the intensive care unit.
S. Finfer (2004)
Cancer statistics, 2013
R. Siegel (2013)
Type III Hypersensitivity
E. M. Opremcak (1995)
Spectral characterization of the binding
R. 1111vec.12085 Punith (2012)
Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P 450 isoenzymes
X. Song (2011)
Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.
X. Song (2011)
Pharmaceutical formulation of HSA hybrid coated iron oxide nanoparticles for magnetic drug targeting.
J. Zaloga (2016)
Interaction of human serum albumin with anticancer agents in vitro.
I. Takahashi (1980)
Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivo
Qiu-sha Tang (2011)
Evaluation of the pattern of human albumin utilization at a university affiliated hospital.
A. H. Talasaz (2012)
A coreshell albumin copolymer nanotransporter for high capacity loading and two - step release of doxorubicin with enhanced antileukemia activity
Y. Wu (2013)
Spectral characterization of the binding and conformational changes of serum albumins upon interaction with an anticancer drug, anastrozole.
R. Punith (2012)
A core-shell albumin copolymer nanotransporter for high capacity loading and two-step release of doxorubicin with enhanced anti-leukemia activity.
Y. Wu (2013)
Cancer statistics
N. Dubrawsky (1989)
Albumin abuse in intensive care medicine
A. Grootendorst (1988)
Serum proteins as drug carriers of anticancer agents: a review.
F. Kratz (1998)
Type III hypersensitivity reaction with immune complex deposition in 2 critically ill dogs administered human serum albumin
Cassandra Powell Dvm (2013)
Review of the rational use
T. 1016j.ejpb.2016.01.017 Zhou (2013)
Fortification of blood plasma from cancer patients with human serum albumin decreases the concentration of cisplatin-derived toxic hydrolysis products in vitro.
T. T. Morris (2014)
A comprehensive computational study
M. G. Papadopoulos (2015)
Adherence 7, 1207–1212
Patient Prefer (2016)
Comparative Analysis
Daniel S. Weld (1987)
The Anticancer Activity and HSA Binding Properties of the Structurally Related Platinum (II) Complexes
R. Yousefi (2012)
Comparative Analysis
A. Conversi (2009)
MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1
Kai-xuan Sun (2015)
[Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
Jinxi He (2015)
Review of the rational use and adverse reactions to human serum albumin in the People’s Republic of China
T. Zhou (2013)
[Rational use of albumin].
E. Sikuler (2000)
Human albumin solution for resuscitation and volume expansion in critically ill patients.
I. Roberts (2011)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar